Auswahl der wissenschaftlichen Literatur zum Thema „Modèle de xénogreffe“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Modèle de xénogreffe" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Modèle de xénogreffe"
Sola, Brigitte, und Mélody Caillot. „L’embryon de poule“. médecine/sciences 38, Nr. 10 (Oktober 2022): 795–99. http://dx.doi.org/10.1051/medsci/2022123.
Der volle Inhalt der QuelleGuisier, F., M. Salaün, P. Bohn, P. Vera und L. Thiberville. „Micro-imagerie in vivo de l’apoptose dans un modèle de xénogreffe murine d’adénocarcinomes pulmonaires humains“. Revue des Maladies Respiratoires 31 (Januar 2014): A137. http://dx.doi.org/10.1016/j.rmr.2013.10.479.
Der volle Inhalt der QuelleGuisier, F., M. Salaun, P. Bohn, M. Cornic, J. M. Picquenot, P. Vera und L. Thiberville. „Micro-imagerie in vivo de l’apoptose dans un modèle de xénogreffe murine d’adénocarcinomes pulmonaires humains“. Revue des Maladies Respiratoires 31, Nr. 7 (September 2014): 658. http://dx.doi.org/10.1016/j.rmr.2014.04.032.
Der volle Inhalt der QuelleGuisier, F., M. Salaün, P. Bohn, P. Vera und L. Thiberville. „Imagerie microscopique quantitative in vivo de l’apoptose dans un modèle de xénogreffe murine d’adénocarcinome pulmonaire“. Revue des Maladies Respiratoires 31, Nr. 9 (November 2014): 880. http://dx.doi.org/10.1016/j.rmr.2014.06.015.
Der volle Inhalt der QuelleDJELLOULI, Djamel, Naïm JALAL, Amor BOUARICHA, Abdelaziz BOUCHELAGHEM und Mustapha ZIDI. „Etude du comportement mécanique de l’anévrisme de l’aorte abdominale créé par le modèle de xénogreffe de rat“. Revue des composites et des matériaux avancés 27, Nr. 1-2 (30.06.2017): 45–56. http://dx.doi.org/10.3166/rcma.27.45-56.
Der volle Inhalt der QuelleSurdez, D., und E. Daudigeos-Dubus. „PDX ou xénogreffe dérivée de la tumeur du patient, la renaissance d’un modèle oublié : son implication dans la recherche et la clinique de demain“. Revue d'Oncologie Hématologie Pédiatrique 4, Nr. 4 (Dezember 2016): 237–45. http://dx.doi.org/10.1016/j.oncohp.2016.10.017.
Der volle Inhalt der QuelleBerger, F., V. Dangles-Marie, E. Marangoni und L. Belin. „Pertinence des designs expérimentaux utilisant des modèles de xénogreffes dérivées de patients dans les études précliniques“. Revue d'Épidémiologie et de Santé Publique 64 (Mai 2016): S127—S128. http://dx.doi.org/10.1016/j.respe.2016.03.025.
Der volle Inhalt der QuelleDevaud, C., B. Rousseau, V. Pitard, S. Netzer, P. Costet, J. F. Moreau, F. Couillaud, J. Dechanet-Merville und M. Capone. „R93: Rôle antitumoral de lymphocytes T gamma delta humains dans un modèle murin de xénogreffes de carcinome colique métastatique“. Bulletin du Cancer 97, Nr. 4 (Oktober 2010): S52—S53. http://dx.doi.org/10.1016/s0007-4551(15)31012-2.
Der volle Inhalt der QuelleFerragu, M., S. Bellal, V. Lecore, L. Vergori, C. Martinez und P. Bigot. „Effets des microvésicules sur la croissance et l’environnement de xénogreffes de carcinome rénal à cellules claires dans un modèle Murin“. Progrès en Urologie - FMC 32, Nr. 3 (November 2022): S86—S87. http://dx.doi.org/10.1016/j.fpurol.2022.07.098.
Der volle Inhalt der QuelleTheillet, C. „R170 - Oral: Les xénogreffes de tumeurs primitives comme modèles de la maladie cancéreuse ; entre lignées cellulaires et collections de tumeurs“. Bulletin du Cancer 97, Nr. 4 (Oktober 2010): S83. http://dx.doi.org/10.1016/s0007-4551(15)31091-2.
Der volle Inhalt der QuelleDissertationen zum Thema "Modèle de xénogreffe"
Soquet, Jérôme. „Modulation médicamenteuse des calcifications valvulaires dans un modèle ovin de xénogreffe aortique“. Electronic Thesis or Diss., Université de Lille (2022-....), 2023. http://www.theses.fr/2023ULILS061.
Der volle Inhalt der QuelleAortic stenosis (AS) is the most frequent and the most lethal valvular heart disease in the elderly in high-income countries
Angioi, Duprez Karine. „La souris nude : un modèle d'études expérimentales des xénogreffes de tissus humains“. Nancy 1, 1993. http://www.theses.fr/1993NAN19430.
Der volle Inhalt der QuelleBousquet, Guilhem. „Transgénèse et xénogreffe : deux stratégies expérimentales pour les thérapies innovantes en cancérologie“. Paris 7, 2011. http://www.theses.fr/2011PA077142.
Der volle Inhalt der QuelleCancers are frequent diseases and leading causes of mortality in the world. They are a major health care problem. Despite a significant improvement in prognosis of patients since the last 20 years, the development of innovating therapeutical agents is highly required, challenging research in oncology. In addition, a preclinical knowledge of mechanisms of action and biomarkers of response is crucial for not missing the clinical development of these new drugs. The preclinical pharmacological models currently used since 30 years are clearly insufficient, as only 5% of tested agents finally succeed in being active in patients. I had the opportunity to use two different experimental murine models for the development of two innovating therapies : 1)The double transgenic model which develop colorectal tumors mimicking the human pathology. First, we demonstrated its pharmacological relevance regarding to cytotoxic currently used in patients. Second, we showed that Dbait, a DNA repair inhibitor, may be an effective additional treatment for increasing the efficacy of chemotherapy in colon or rectal cancer, independently of KRAS status. 2)Mice xenografted with human tumor cell lines with sequential cellular and molecular studies. We demonstrated that the specific effect of sunitinib, mainly a VEGFR inhibitor, differs according to the tumor type. This effect was first identified on neoangiogenic microvessels, but a direct effect on tumor cells was also found and related to sunitinib target expression
Ruellan, Anne-Lise. „Ciblage du syndecan-1 dans un modèle de xénogreffe de carcinome mammaire en radioimmunothérapie alpha et bêta“. Nantes, 2009. https://archive.bu.univ-nantes.fr/pollux/show/show?id=831fcdb6-7ee2-42c1-b1a0-650f5021b5c5.
Der volle Inhalt der QuelleRadioimmunotherapy has for principle to target the surface of cancer cells to destroy them. In most of the cases, the used vectors are spécific antibodies of tumoral antigens. The use of radionucleids presenting different physical characteristics allow to adapt the treatment to every type of tumors. So, bêta particles (β), of weak energy, possess a long scope and are adapted to the irradiation of bulky tumors. On the other hand, the alpha particles, very energetic, of wich is limited, would be better suited for the treatment of isolated cells or micrometastasis. In this frame, we developped a murin model of breast cancer to estimate the relevance particles, in this pathology, by targeting syndecan-1 (CD138) associated with Iodine 131. This antigen is over express on multiple myeloma cells and on several carcinomas including breast, prostate, colon, renal cell and hepatocellular carcinoma. In breast carcinomas the over expression of syndecan-I correlates with poor prognosis and an aggressive phenotype. We showed the efficiency of the targeting syndecan-1 in radioimmunotherapy β, with a regression of the tumoral volume. Besides, although the structure of solid tumor is little favorable to the treatment in RIT alpha, we showed that it was possible to obtain the regression of mammary tumor by this technique, using Bimuth 213, this independently of the specificity of the used antibody. This regression seems essentially due to the tumoral neo-vascularization targeting. We thus tried to validate this hypothesis or this model by targeting specifically the tumoral neo-vessels in RIT alpha
Capito, Carmen. „Développement du pancréas humain embryonnaire ex vivo / in vivo : La greffe musculaire : un nouveau modèle d'étude longitudinale et dynamique“. Phd thesis, Université René Descartes - Paris V, 2013. http://tel.archives-ouvertes.fr/tel-00862466.
Der volle Inhalt der QuelleBenomar, Abdeljalil. „Interactions macrophages - cellules tumorales : analyse dans un modèle de xénogreffe de lignées cellulaires de mélanomes humains chez la souris Nude“. Lyon 1, 1985. http://www.theses.fr/1985LYO1W033.
Der volle Inhalt der QuelleCoutier, Stéphanie. „Effet de l'irradiance sur la déplétion photochimique en oxygène après photosensibilisation de sphéroï͏̈des et de xénogreffes tumorales par la méta-tétra(hydroxyphényl)chlorine : activation par photosensibilisation de monocytes différenciés en macrophages“. Nancy 1, 2001. http://www.theses.fr/2001NAN11316.
Der volle Inhalt der QuelleThiollier, Clarisse. „Modélisation et caractérisation des leucémies aiguës mégacaryoblastiques pédiatriques“. Paris 7, 2013. http://www.theses.fr/2013PA077126.
Der volle Inhalt der QuelleAcute megakaryoblastic leukemia (AMKL) is a heterogeneous subtype of acute myeloid leukemia, more frequent in children and associated with a poor prognosis. Until recently, two distinct subgroups have been characterized in pediatric AMKL: 1-children with Down syndrome that acquire GATAI mutation in virtually ail cases and 2-children with a translocation t(l;22)(pl3;q!3), that leads to the expression of the oncogenic OTT-MAL fusion protein. I have developed xenotransplantation models of human AMKL cells in immunodeficient mice and have obtained murine models of human AMKL. High throughput sequencing of RNA from leukemic cells allowed to identify a third subgroup defined by a new ETO2-GLIS2 fusion resulting from an inversion of chromosome 16 and present in 31% of non-Down syndrome paediatric AMKL. The ETO2 transcription factor is expressed during normal haematopoiesis and controls the expression of genes implicated in terminal megakaryocytic differentiation. GLIS2 is similar to GLI factors controlling the response to Hedgehog pathway activation and is not expressed during normal haematopoiesis. The high expression of Hedgehog pathway target genes in patients with the ETO2-GLIS2 fusion in comparison to other patients suggests that aberrant activation of Hedgehog pathway is involved in leukemic transformation. A fourth subgroup is defîned by an HOX genes transcriptional signature sometimes associated with MLL-AF9 and NUP9§-KDM5a fusions. Finally, we have used these models to show the efficacy of Aurora A kinase inhibitors to inhibit the proliferation of patient cells in vivo that suggests the interest of these molecules as new therapeutic strategy
Mazzola, Clarisse. „Réalisation d'un modèle de xénogreffe rénale utilisant des embryons de poule permettant d'analyser en amont la sensibilité des cellules tumorales de chaque patient ayant un cancer du rein métastatique aux différents agents de thérapie ciblée“. Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS471.
Der volle Inhalt der QuelleObjective: Approximately 30% of patients with metastatic renal cancer are resistant to targeted therapy agents. The other patients will eventually develop long-term therapeutic resistances. An improvement in the clinician's ability to predict therapeutic response before treatment initiation could improve patients' prognosis. The aim of our projet was to develop a patient-derived xenograft models to be able to test the sensibility of each patient's renal tumor cells to the different available targeted therapy agent prior to treatment.Methods: The chicken embryo chorioallantoic membrane has been the base of our model. In a first phase of our work, a xenograft of human kidney tumor cells has been carried out in order to verify that the histologic and phenotypic characteristics of the original tumors were preserved in the xenografts performed on our model. As a second step, fragments of the kidney tumor speciments of 5 patients undergoing cytoreductive nephrectomy in our hospital center were grafted on our model (> 60/patient). Different targeted therapy agents were tested on the xenografts we performed.Results: The histopathologic and phenotypic characteristics of the original renal tumors were preserved in our xenografts. There was intra-tumor spatial heterogeneity in terms of sensitivity in different targeted therapy agents. There was also a nucleotide polymorphism within the different regions of each renal tumor.Conclusion: This patient-derived renal xenograft model could be useful prior to treatment for the evaluation of each patients'renal tumor cells to the different available targeted therapy agents. This model could make it possible to personalize the treatment of each metastatic kidney cancer patient, prior to systemic treatment. A prospective evaluation of our model could help assess the potential clinical benefits of its use
Van, Zoggel Johanna. „Dermaseptine B2 : un peptide antimicrobien issue des sécrétions de peau de Phyllomedusa bicolore avec des activités antitumorales et angiostatiques“. Thesis, Paris Est, 2010. http://www.theses.fr/2010PEST0051.
Der volle Inhalt der QuelleThe skin secretions of neotropical and South American frogs contains large amounts of a widerange of biological active molecules. Commonly studied are peptides with antimicrobialactivities. In this study we have postulated that the skin secretions from the South Americanfrog Phyllomedusa bicolor contain molecules with antitumor and angiostatic activities. Twowell known cationic alpha helical antimicrobial peptides of the dermaseptin (Drs) family wereidentified to have these activities: Drs B2 and Drs B3. Both peptides inhibited proliferationand colony formation of various tumor cell lines, and the proliferation and capillary formationof endothelial cell in vitro. Furthermore, Drs B2 inhibited tumor growth in a PC3 xenograftmodel in vivo.Research on the mechanism of action of Drs B2 on tumor cells PC3 demonstrated a rapidincreasing amount of cytosolic LDH, no activation of caspase-3, -9 or -8, and no changes inmitochondrial membrane potential. These data together indicate that Drs B2 does not act byapoptosis but possibly could fix to the tumor cell surface, disrupt the cellular plasmamembrane leading to its death by necrosis.In conclusion, Drs B2 could be an new interesting and promising pharmacological leadermolecule for the treatment of cancer. Its antitumor and angiostatic activities, especially itsselective targeting of tumoral cells with micro molar concentrations propose Drs B2 as anpotential candidate for the development of a new efficient targeting therapy against cancer